Jun 22, 2020 7:00am EDT Sutro Biopharma Presents New Preclinical Data at 2020 AACR Virtual Annual Meeting II Suggesting Synergy between its STRO-002 Antibody-Drug Conjugate and Immune Checkpoint Inhibitors Resulting in Tumor Regression and Adaptive Anti-Tumor Immunity
Jun 09, 2020 7:00am EDT Sutro Biopharma to Present New Preclinical Data on its STRO-002 Antibody-Drug Conjugate at the Upcoming AACR 2020 Virtual Meeting on June 22, 2020
May 21, 2020 7:15am EDT Sutro Biopharma Expands Senior Management with the Additions of Vice President of Clinical Development and Vice President of Finance and Controller
May 21, 2020 7:00am EDT Sutro Biopharma Adds Two Exceptional Leaders to Advisory Boards-- Carlos Paya, MD, PhD, and Lainie Martin, MD
May 14, 2020 4:01pm EDT Sutro Biopharma Announces Closing of $98.0 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares
May 11, 2020 4:15pm EDT Sutro Biopharma Reports First Quarter 2020 Financial Results and Recent Business Highlights and Developments
Apr 27, 2020 12:01am EDT Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer
Apr 20, 2020 4:35pm EDT Sutro Biopharma to Host Conference Call on April 27, 2020, to Provide Clinical Update on its STRO-002 Antibody-Drug Conjugate
